Announced entry into an agreement to be acquired by XOMA Royalty Corporation for between $1.16 and $1.24 per share in cash, plus a contingent value right related to LAVA’s two partnered assets and ...

Reports Q2 revenue $0 vs. $0 last year. As of June 30, Lava had cash, cash equivalents, and short-term investments of $56.2M vs. $76.6M as of ...

Key Points Revenue (GAAP) beat estimates by 39.5% in Q2 2025, rising to $13.1 million on substantial milestone receipts. Recurring royalty income remained modest, with only $2.6 million from ...

EMERYVILLE, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, reported its 2025 second quarter and year to date financial results and ...

SERB Pharmaceuticals plans to buy Y-mAbs Pharmaceuticals in a $412 million all-cash deal. CorMedix bought Melinta ...

DelveInsight's CLK Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive unders ...

Explore XOMA's shift to M&A with CVRs, recent LVTX & HLVX deals, and their potential impact. Learn why analysts maintain a ...

XOMA Royalty Corporation is to buy fellow US firm LAVA Therapeutics for $1.16 to $1.24 per share in cash, plus a contingent value right (CVR), the companies announced Monday.

Fintel reports that on August 5, 2025, Jefferies downgraded their outlook for LAVA Therapeutics N.V. (NasdaqGS:LVTX) from Buy ...

The firm will continue developing Lava's two partnered bispecific gamma delta T-cell engager programs with Pfizer and Johnson & Johnson.

The neuroendocrine prostate cancer treatment space will experience significant changes during the forecast period of 2025–2034, owing to the launch o ...